Founded in 2020, Cargene Therapeutics Pte. Ltd. is a biopharmaceutical company developing innovative oligonucleotide therapeutics for liver, cardiometabolic and ophthalmic disorders, with the headquarter in Singapore and operations in USA and China. Using proprietary platforms based on novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly efficacious, specific, and stable nucleic acid-based medicines for the treatment of a broad range of diseases.